John Simmons

Company: Natera

Job title: Global Vice President - Biopharma

Seminars:

The Use of ctDNA MRD in Clinical Development 9:30 am

Backed by >50 peer reviewed publications and >200 congress presentations, Signatera’s prognostic and predictive capabilities has been demonstrated across tumor histologies Signatera has been shown to identify high-risk patients who may benefit from investigational/novel therapies; more interventional trials are needed for these populations Rapid growth in Signatera utilization, especially in colorectal, breast, and bladder cancers,…Read more

day: Day Two